抗癫痫药物单药治疗与卒中后癫痫患者死亡率之间的关联
瑞典一项基于登记数据的队列研究纳入2577例卒中后癫痫成人患者,分析不同抗癫痫药物单药治疗与全因死亡及心血管死亡的关系。以卡马西平为参照,拉莫三嗪单药治疗与较低的全因死亡和心血管死亡风险相关,丙戊酸则与较高的全因死亡和心血管死亡风险相关,左乙拉西坦与较低的心血管死亡风险相关但全因死亡无显著差异。
要点
- 与卡马西平相比,拉莫三嗪单药治疗的全因死亡风险较低(HR 0.72,95%CI 0.60-0.86)。
- 与卡马西平相比,丙戊酸单药治疗的全因死亡风险较高(HR 1.40,95%CI 1.23-1.59)。
- 左乙拉西坦与较低的心血管死亡风险相关(HR 0.77,95%CI 0.60-0.99),但全因死亡无显著差异。
核心结论
- 该队列研究提示卒中后癫痫患者接受不同抗癫痫药物单药治疗的生存率存在差异。
- 与卡马西平相比,拉莫三嗪单药治疗者的全因死亡和心血管死亡风险较低。
- 与卡马西平相比,丙戊酸单药治疗者的全因死亡和心血管死亡风险较高。
- 与卡马西平相比,左乙拉西坦与较低的心血管死亡风险相关,但全因死亡无显著差异。
研究设计与样本
- 研究为队列研究,使用瑞典关联登记库的个体水平数据。
- 纳入2005年7月1日至2010年12月31日期间发生急性卒中的所有瑞典成人,且癫痫发作于2014年12月31日之前。
- 共2577例接受持续抗癫痫药物单药治疗的患者符合条件,其中男性1400例(54%)。
- 中位年龄78岁(IQR 69-85岁)。
- 数据分析时间为2019年5月27日至2021年4月8日。
主要发现
- 与卡马西平相比,全因死亡的调整风险比为:拉莫三嗪0.72(95%CI 0.60-0.86),左乙拉西坦0.96(95%CI 0.80-1.15),丙戊酸1.40(95%CI 1.23-1.59),苯妥英1.16(95%CI 0.88-1.51),奥卡西平1.16(95%CI 0.81-1.66)。
- 与卡马西平相比,心血管死亡的调整风险比为:拉莫三嗪0.76(95%CI 0.61-0.95),左乙拉西坦0.77(95%CI 0.60-0.99),丙戊酸1.40(95%CI 1.19-1.64),苯妥英1.02(95%CI 0.71-1.47),奥卡西平0.71(95%CI 0.42-1.18)。
- 全因死亡分析采用Cox比例风险回归,以卡马西平为参照。
- 心血管死亡分析采用Fine-Gray竞争风险回归模型。
临床怎么用
- 作者认为,该队列研究的结果提示卒中后癫痫患者接受不同抗癫痫药物单药治疗的生存率存在差异,原文未据此给出具体用药推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: There is little evidence to guide the choice of antiseizure medication (ASM) for patients with poststroke epilepsy. Theoretical concerns about detrimental effects of ASMs on survival exist. Enzyme-inducing drugs could interfere with secondary stroke prevention. The US Food and Drug Administration recently issued a safety announcement about the potential proarrhythmic properties of lamotrigine. OBJECTIVE: To investigate whether mortality varies with specific ASMs among patients with poststroke epilepsy. DESIGN, SETTING, AND PARTICIPANTS: A cohort study was conducted using individual-level data from linked registers on all adults in Sweden with acute stroke from July 1, 2005, to December 31, 2010, and subsequent onset of epilepsy before December 31, 2014. A total of 2577 patients receiving continuous ASM monotherapy were eligible for the study. Data were analyzed between May 27, 2019, and April 8, 2021. EXPOSURES: The dispensed ASM (Anatomical Therapeutic Chemical code N03A) determined exposure status, and the first dispensation date marked the start of treatment. MAIN OUTCOMES AND MEASURES: The primary outcome, all-cause death, was analyzed using Cox proportional hazards regression with carbamazepine as the reference. Cardiovascular death (International Statistical Classification of Diseases and Related Health Problems, Tenth Revision codes I0-I99 as the underlying cause) was assessed using Fine-Gray competing risk regression models. RESULTS: A total of 2577 patients (1400 men [54%]; median age, 78 years [IQR, 69-85 years]) were included. The adjusted hazard ratio of all-cause death compared with carbamazepine was 0.72 (95% CI, 0.60-0.86) for lamotrigine, 0.96 (95% CI, 0.80-1.15) for levetiracetam, 1.40 (95% CI, 1.23-1.59) for valproic acid, 1.16 (95% CI, 0.88-1.51) for phenytoin, and 1.16 (95% CI, 0.81-1.66) for oxcarbazepine. The adjusted hazard ratio of cardiovascular death compared with carbamazepine was 0.76 (95% CI, 0.61-0.95) for lamotrigine, 0.77 (95% CI, 0.60-0.99) for levetiracetam, 1.40 (95% CI, 1.19-1.64) for valproic acid, 1.02 (95% CI, 0.71-1.47) for phenytoin, and 0.71 (95% CI, 0.42-1.18) for oxcarbazepine. CONCLUSIONS AND RELEVANCE: This cohort study's findings suggest differences in survival between patients treated with different ASMs for poststroke epilepsy. Patients receiving lamotrigine monotherapy had significantly lower mortality compared with those receiving carbamazepine. The opposite applied to patients prescribed valproic acid, who had a higher risk of cardiovascular and all-cause death. Levetiracetam was associated with a reduced risk of cardiovascular death compared with carbamazepine, but there was no significant difference in overall mortality.
引用
- Larsson D, Baftiu A, Johannessen Landmark C, et al. Association Between Antiseizure Drug Monotherapy and Mortality for Patients With Poststroke Epilepsy. JAMA Neurol. 2022. PMID: 34902006. doi:10.1001/jamaneurol.2021.4584
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。